Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome
Modern Pathology · 2023
DOI: 10.1016/j.modpat.2023.100158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Júlia Canet-Hermida und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: European Regional Development Fund, Gobierno de Espana Ministerio de Economia y Competitividad, España Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Women with Lynch syndrome (LS) are at increased risk of endometrial cancer (EC), among other tumors, and are characterized by mismatch repair (MMR) deficiency and microsatellite instability (MSI). While risk-reducing gynecologic surgeries effectively decrease EC incidence, doubts arise regarding the appropriate timing of the surgery. We explored the usefulness of highly sensitive MSI (hs-MSI) assessment in endometrial aspirates for individualizing gynecologic surveillance in LS carriers. Ninety-three women with LS, 25 sporadic EC patients (9 MMR-proficient and 16 MMR-deficient), and 30 women with benign gynecologic disease were included in this study. hs-MSI was assessed in prospectively collected endometrial aspirates in 67 LS carriers, EC cases, and controls. MMR, PTEN, ARID1A, and PAX2 protein expression patterns were evaluated in the LS samples. Follow-up aspirates from 8 LS carriers were also analyzed. Elevated hs-MSI scores were detected in all aspirates from MMR-deficient EC cases (3 LS and 16 sporadic) and negative in aspirates from controls and MMR-proficient EC cases. Positive hs-MSI scores were also detected in all 4 LS aspirates reported as complex hyperplasia. High hs-MSI was also present in 10 of 49 aspirates (20%) from LS carriers presenting a morphologically normal endometrium, where MMR protein expression loss was detected in 69% of the samples. Interestingly, the hs-MSI score was positively correlated with MMR-deficient gland density and the presence of MMR-deficient clusters, colocalizing PTEN and ARID1A expression loss. High hs-MSI scores and clonality were evidenced in 2 samples collected up to 4 months before EC diagnosis; hs-MSI scores increased over time in 5 LS carriers, whereas they decreased in a patient with endometrial hyperplasia after progestin therapy. In LS carriers, elevated hs-MSI scores were detected in aspirates from premalignant and malignant lesions and normal endometrium, correlating with MMR protein loss. hs-MSI assessment and MMR immunohistochemistry may help individualize EC risk assessment in women with LS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Ca…
- Pathology Department, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
- Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain.
- Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
- Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Förderung
- European Regional Development Fund
- Gobierno de Espana Ministerio de Economia y Competitividad
- España Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- CIBER
- Xarxa de Bancs de Tumors de Catalunya
- Ministerio de Economía y Competitividad
- Ministerio de Ciencia e Innovación
Zitieren
APA
Canet-Hermida, J., Marín, F., Dorca, E., Dueñas, N., Costas, L., Salinas, M., Velasco, À., Peremiquel-Trillas, P., Paytubi, S., Ponce, J., Fernández, S., Martínez, J. M., Cárdenas, L., Taltavull, A., Alemany, L., Meléndez, C., Oliveras, G., Vidal, A., Capellá, G., …, & Pineda, M. (2023). Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100158
Vancouver
Canet-Hermida J, Marín F, Dorca E, Dueñas N, Costas L, Salinas M, et al. Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100158
BibTeX
@article{CanetHermida2023,
author = {Canet-Hermida, Júlia and Marín, Fátima and Dorca, Eduard and Dueñas, Núria and Costas, Laura and Salinas, Mònica and Velasco, Àngela and Peremiquel-Trillas, Paula and Paytubi, Sònia and Ponce, Jordi and Fernández, Sergi and Martínez, José Manuel and Cárdenas, Laura and Taltavull, Anna and Alemany, Laia and Meléndez, Cristina and Oliveras, Glòria and Vidal, August and Capellá, Gabriel and López-Bonet, Eugeni and Brunet, Joan and Matias-Guiu, Xavier and Pineda, Marta},
title = {Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome},
journal = {Modern Pathology},
year = {2023},
doi = {10.1016/j.modpat.2023.100158}
}
EUVIMED